FIELD: biotechnology.
SUBSTANCE: invention discloses the use of exosomes loaded with fas-associated factor 1 (FAF1), and a method of treating cancer. Essence of the invention consists in the extraction of exosomes loaded with the FAF1 protein from HEK 293 cells, in which FAF1 is overexpressed, having a known tumour-suppressing function, then exosomes loaded with FAF1 protein are introduced into the tumour model, where pancreatic cancer cells (MIA PaCa-2), lung cancer cells (A549), colon cancer cells (HCT 116), liver cancer cells (Hep3B), breast cancer cells (MDA-MB-231), kidney cancer cells (Caki-1) and cervical cancer cells (HeLa cells) were transplanted into nude mice by intratumoral injection and found that tumour growth inhibition effects were observed, more pronounced than in the control group not treated with FAF1.
EFFECT: thus, exosomes loaded with FAF1, according to the present invention, can be used as a therapeutic agent for treating various types of cancer.
12 cl, 19 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXO-SOMATIC BIOMARKERS | 2015 |
|
RU2712223C2 |
| NEW MEDICAL AGENTS AND USE THEREOF | 2015 |
|
RU2739073C2 |
| COMPOSITIONS AND METHODS FOR STIMULATING NATURAL KILLER CELLS | 2020 |
|
RU2839664C2 |
| PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| VESICLES CONTAINING PTEN INHIBITOR AND THEIR USE | 2019 |
|
RU2800729C2 |
| NUCLEOTIDE SEQUENCE EXPRESSING ANCHOR PROTEIN OF EXOSOMES FOR USE AS VACCINE | 2017 |
|
RU2761642C2 |
